Anesthesia

RALP combines two independently stressful insults that compound each other: pneumoperitoneum (raised intra-abdominal pressure, CO2 absorption) and steep Trendelenburg (30-45 deg head-down for hours) - causing cephalad fluid shift, raised ICP/IOP, reduced pulmonary compliance, and altered cerebral autoregulation.

• Increased IOP from elevated episcleral venous pressure and choroidal congestion, worsens with duration
• Postoperative visual loss (POVL) - rare but devastating, mainly ischemic optic neuropathy from prolonged positioning, venous congestion, relative hypotension, anemia, prolonged duration
• Conjunctival/periorbital edema (chemosis) - usually self-limiting
• Prevention: minimize angle/duration, avoid excessive crystalloid, maintain hemoglobin, careful eye protection/padding

• Reduced FRC/compliance from cephalad viscera and diaphragm displacement
• Increased peak/plateau pressures - pressure-controlled ventilation often preferred
• Atelectasis in dependent regions - recruitment + PEEP balanced against hemodynamic/ICP effects
• Risk of endobronchial intubation from cephalad mediastinal shift - re-auscultate after final positioning
• CO2 absorption requires increased minute ventilation; rare capnothorax/subcutaneous emphysema

• Cerebral autoregulation generally preserved but hypercapnia (vasodilator) + venous congestion can push CBV/ICP higher
• Airway/facial edema may warrant cuff-leak test or delayed extubation after prolonged cases
• Relative contraindications: pre-existing raised ICP, cerebrovascular disease, severe cardiopulmonary disease, glaucoma

Controlled pressure-limited ventilation with titrated PEEP; invasive arterial monitoring for prolonged/high-risk cases; judicious/restrictive fluid management; maintain hemoglobin; meticulous eye protection; minimize total steep time; gradual return to supine with hemodynamic monitoring.

Structure the answer explicitly across ocular, respiratory, and cerebrovascular systems as demanded. Name ischemic optic neuropathy specifically and mention the role of fluid restriction.

The ARDS lung is functionally a ""baby lung"" - only a fraction of normal-sized lung tissue remains aerated/compliant. Ventilating this small volume with conventional tidal volumes causes VILI via volutrauma, barotrauma, atelectrauma, and biotrauma - driving low tidal volume, adequate PEEP, and prone positioning strategy.

• ARDSNet target: Vt 4-8 mL/kg (commonly start 6 mL/kg) of predicted/ideal body weight (PBW), NOT actual body weight
• Why PBW: lung size correlates with height/sex, not fat/edema-related weight
• IBW formula: Male = 50 + 0.91x(height cm - 152.4); Female = 45.5 + 0.91x(height cm - 152.4)
• Plateau pressure target <30 cmH2O (some evidence supports <=27-28 when feasible)
• Permissive hypercapnia accepted (pH tolerated to 7.20-7.25) - caution with raised ICP/RV dysfunction

PEEP: maintains recruitment, prevents atelectrauma. Higher PEEP favored in moderate-severe ARDS (P/F<200) per patient-level meta-analyses. Titration via ARDSNet tables, best-compliance, esophageal pressure, or decremental trials.

NMB: early short-course (~48h) infusion considered in P/F<150. ACURASYS (2010) suggested mortality benefit; ROSE (2019) found no difference with light sedation + as-needed NMB - current practice is individualized, not routine.

Indications: P/F<150 on PEEP>=5 and FiO2>=0.6 despite optimization (PROSEVA criteria). Initiate early (24-48h), sessions >=16 h/day.

Contraindications: unstable spine fracture, raised ICP, recent open abdomen, hemodynamic instability, late pregnancy.

Write out the exact IBW formula. Mention driving pressure with the Amato 2015 reference and >15 cmH2O threshold. Show awareness of the ACURASYS vs ROSE NMB evidence evolution.

Modern MTP has shifted from ""1:1:1 ratio-driven"" empiric resuscitation toward viscoelastic-guided, goal-directed component therapy, recognizing trauma-induced coagulopathy is complex and multifactorial rather than simply dilutional.

Activation scores: ABC score (penetrating mechanism, positive FAST, SBP<=90, HR>=120; score>=2 predicts need). Shock Index (HR/SBP>1.0). Clinical gestalt should prompt early activation regardless of formal score.

TXA: 1g IV loading over 10 min + 1g infusion over 8h, within 3 hours of injury (CRASH-2). Benefit is time-dependent - beyond 3h, no benefit/possible harm.

PCC: concentrated factors II,VII,IX,X - rapid VKA reversal; faster/lower volume than FFP; caution re: thrombotic risk.

Quote the CRASH-2 TXA dosing/timing exactly (1g bolus + 1g over 8h, within 3h). Give a clear TACO vs TRALI comparison. Mention ""fibrinolysis shutdown"" as a distinct phenotype.

Brain death is the complete and irreversible cessation of all brain and brainstem function, legally equivalent to death under India's THOA (1994, amended 2011/2014). Once declared, focus shifts entirely to active multiorgan donor optimization.

Preconditions: known cause of irreversible brain injury; exclusion of reversible causes (hypothermia, severe metabolic/endocrine disturbance, drug/NMB effect, profound uncorrected hypotension).

Explicitly state the THOA requirement of two examinations by a panel of four doctors, separated by the standard interval, none from the transplant team. Frame donor management around the autonomic-storm-to-hormonal-collapse narrative.

POCUS protocols transform bedside ultrasound into a structured diagnostic pathway - RUSH systematically interrogates the ""pump, tank, and pipes"" to rapidly differentiate shock etiology; BLUE uses characteristic named artifact patterns to diagnose acute respiratory failure within minutes, without moving the patient.

Real-time, repeatable, bedside - avoids transporting an unstable patient. Reduces diagnostic time from hours to minutes. Guides therapeutic decisions (fluid responsiveness, tamponade/pneumothorax, line placement). Complements, does not replace, clinical exam/formal imaging.

BLUE profiles: A-profile+DVT = PE; B-profile bilateral = pulmonary edema/ARDS; asymmetric B/consolidation = pneumonia; absent sliding + lung point = pneumothorax; PLAPS profile = basal pneumonia.

RUSH and BLUE can be combined/sequenced for undifferentiated hypotension + respiratory distress. Serial exams track response to therapy. Limitations: operator-dependence, body habitus, training requirement; cannot fully replace comprehensive echo.

Memorize and write ""pump, tank, pipes"" explicitly. Name at least A-profile/B-profile/lung point findings with their diagnoses. Mention POCUS avoids transporting an unstable patient.

Cardiac surgery-associated AKI is multifactorial - CPB-related hemodilution/inflammation, non-pulsatile flow/hypoperfusion, hemolysis-related nephrotoxicity, and embolic phenomena. Even mild AKI (KDIGO Stage 1) is independently associated with increased mortality.

Diagnosis requires only ONE criterion; stage by whichever indicates more severe injury. Risk factors: pre-existing CKD/diabetes/age, prolonged CPB/cross-clamp time, hemodilution, hemolysis, non-pulsatile flow, embolic phenomena, nephrotoxin exposure, low cardiac output.

Serial creatinine trend, hourly urine output, urinalysis/microscopy, fractional excretion, novel biomarkers (NGAL, cystatin C, TIMP-2xIGFBP7), renal ultrasound if needed, hemodynamic/echo assessment.

Current consensus (post-STARRT-AKI): a ""watchful-waiting"" strategy - initiate based on absolute indications or clear deterioration rather than routine early initiation. CRRT (vs IHD) preferred in hemodynamically unstable patients due to gentler, continuous fluid/solute removal.

Write out the full KDIGO staging table with exact ratios/thresholds. Quote the AEIOU mnemonic. Name the STARRT-AKI trial and its no-benefit conclusion explicitly.

Modern anesthesia workstations are engineered around multiple, layered, independent safety systems - each addressing a specific historically-documented failure mode. The shift from purely mechanical/pneumatic safeguards to integrated electronic monitoring is the most significant recent advance.

• Agent-specific keyed filling systems prevent mis-filling
• Vaporizer interlock system prevents simultaneous engagement of >1 vaporizer
• Inline gas analyzers identify agent and cross-check dial setting

Explicitly contrast mechanical vs electronic hypoxic guard mechanisms. Explain fresh gas decoupling with a clear ""why it matters"" framing rather than just naming it.

All processed-EEG depth-of-anesthesia monitors are proprietary, manufacturer-derived statistical indices built from raw frontal EEG - not direct measures of consciousness - each using different mathematical approaches, all sharing vulnerability to artifact and agent-specific calibration issues.

State Entropy (SE, 0.8-32 Hz, cortical only) vs Response Entropy (RE, 0.8-47 Hz, includes frontal EMG). A widening RE-SE gap indicates EMG/muscle activity - suggesting inadequate analgesia/light anesthesia even if SE looks adequate.

Most beneficial as part of a protocol-driven approach in high-risk populations: TIVA-based anesthesia, neuromuscular-blocked patients, cardiac/trauma surgery, prior awareness history. Should be considered an adjunct to, not a replacement for, sound clinical judgment and end-tidal agent monitoring.

Name the specific mathematical basis distinguishing each monitor. The RE-SE gap and its meaning is frequently tested. Cite B-Unaware/B-Aware/BAG-RECALL to show these monitors reduce but do not eliminate awareness.

The defining advance separating second-generation from first-generation SADs is a dedicated gastric (drain) channel - allowing separation of respiratory and alimentary tracts, addressing the primary safety limitation of first-generation devices: aspiration vulnerability.

• Reduced aspiration risk via dedicated gastric channel (passive drainage + active gastric tube placement)
• Improved seal reduces gastric insufflation during PPV
• Gastric tube test confirms correct placement
• Integrated bite block reduces device damage from biting
• No SAD (any generation) matches a cuffed ETT's aspiration protection - remains contraindicated in high-risk patients (full stomach, severe GERD, bowel obstruction)

State the defining structural difference (gastric channel) immediately. Quote specific OLP numbers for 2-3 named devices. Conclude that even second-generation SADs don't replace a cuffed ETT in high-risk patients.

TCI systems use a computer-controlled pump running a population pharmacokinetic model to achieve/maintain a clinician-set target concentration. Marsh and Schnider differ in derived population and covariates, producing clinically meaningful dosing differences in non-average patients.

Clinician sets a target (plasma or effect-site) -> a 3-compartment PK model (central + 2 peripheral) with population rate constants -> pump calculates/adjusts infusion in real time.

Plasma-targeting: achieves plasma concentration quickly, may overshoot effect-site before equilibration.

Effect-site targeting: uses ke0 to drive faster brain equilibration, more closely tracking clinically relevant concentration.

State explicitly: Marsh uses total body weight with no age adjustment; Schnider uses lean body mass plus age with a fixed central compartment volume. Connect to a practical elderly/obese scenario.